openPR Logo
Press release

U.S. Tardive Dyskinesia Therapeutics Market Size, Trends, Growth, Opportunities | Neurocrine Biosciences, Inc. and Teva Pharmaceutical Industries Ltd.

12-06-2024 07:30 AM CET | Health & Medicine

Press release from: Fortune Business Insights

U.S. Tardive Dyskinesia Therapeutics Market

U.S. Tardive Dyskinesia Therapeutics Market

The U.S. tardive dyskinesia therapeutics market size was worth USD 2.24 billion in 2022 and is projected to grow at a CAGR of 7.8% during the forecast period.

The U.S. Tardive Dyskinesia (TD) Therapeutics Market is gaining momentum as awareness grows around this often debilitating condition. Characterized by involuntary movements, TD arises as a side effect of prolonged use of antipsychotic medications. With increasing research and innovative drug development, the market is poised for significant growth, focusing on improving patient outcomes and maintaining psychiatric stability.

๐——๐—ถ๐˜€๐—ฐ๐—ผ๐˜ƒ๐—ฒ๐—ฟ ๐—ช๐—ต๐—ฎ๐˜ ๐—ฌ๐—ผ๐˜‚'๐—ฟ๐—ฒ ๐— ๐—ถ๐˜€๐˜€๐—ถ๐—ป๐—ด: ๐—š๐—ฒ๐˜ ๐—ฎ ๐—™๐—ฟ๐—ฒ๐—ฒ ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ (๐—ฃ๐——๐—™) ๐—ฆ๐—ฎ๐—บ๐—ฝ๐—น๐—ฒ: https://www.fortunebusinessinsights.com/enquiry/sample/u-s-tardive-dyskinesia-therapeutics-market-107826

๐—ž๐—ฒ๐˜† ๐—œ๐—ป๐—ฑ๐˜‚๐˜€๐˜๐—ฟ๐˜† ๐——๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ๐—บ๐—ฒ๐—ป๐˜

In May 2022, Neurocrine Biosciences unveiled promising findings at the American Psychiatric Association (APA) conference. Their study on INGREZZA capsules (40 mg and 80 mg) demonstrated substantial improvement in TD symptoms over a 48-week period. Both patients and clinicians reported positive results, emphasizing the drug's ability to enhance movement symptoms without compromising psychiatric stability. This breakthrough underscores the company's leadership in the TD therapeutics space.

๐—ง๐—ผ๐—ฝ ๐—–๐—ผ๐—บ๐—ฝ๐—ฎ๐—ป๐—ถ๐—ฒ๐˜€ ๐—ถ๐—ป ๐˜๐—ต๐—ฒ ๐—จ.๐—ฆ. ๐—ง๐—ฎ๐—ฟ๐—ฑ๐—ถ๐˜ƒ๐—ฒ ๐——๐˜†๐˜€๐—ธ๐—ถ๐—ป๐—ฒ๐˜€๐—ถ๐—ฎ ๐—ง๐—ต๐—ฒ๐—ฟ๐—ฎ๐—ฝ๐—ฒ๐˜‚๐˜๐—ถ๐—ฐ๐˜€ ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜

โ€ข Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation) (Japan)
โ€ข Teva Pharmaceutical Industries Ltd. (Israel)
โ€ข Neurocrine Biosciences, Inc. (U.S.)
โ€ข SOM BIOTECH (Spain)
โ€ข Luye Pharma Group (China)

๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐——๐—ฟ๐—ถ๐˜ƒ๐—ฒ๐—ฟ๐˜€

๐—ฅ๐—ถ๐˜€๐—ถ๐—ป๐—ด ๐—ฃ๐—ฟ๐—ฒ๐˜ƒ๐—ฎ๐—น๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ผ๐—ณ ๐—ฃ๐˜€๐˜†๐—ฐ๐—ต๐—ถ๐—ฎ๐˜๐—ฟ๐—ถ๐—ฐ ๐——๐—ถ๐˜€๐—ผ๐—ฟ๐—ฑ๐—ฒ๐—ฟ๐˜€

The increasing prevalence of schizophrenia, bipolar disorder, and other psychiatric conditions is driving the demand for effective TD treatments. As antipsychotics remain the cornerstone of treatment, the need for therapeutics to manage associated side effects like TD is growing.

๐—™๐——๐—” ๐—”๐—ฝ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฎ๐—น๐˜€ ๐—•๐—ผ๐—ผ๐˜€๐˜๐—ถ๐—ป๐—ด ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—–๐—ผ๐—ป๐—ณ๐—ถ๐—ฑ๐—ฒ๐—ป๐—ฐ๐—ฒ

Recent FDA approvals for drugs like valbenazine have enhanced market dynamics, providing patients and healthcare providers with reliable, well-studied treatment options.

๐—š๐—ฟ๐—ผ๐˜„๐—ถ๐—ป๐—ด ๐—”๐˜„๐—ฎ๐—ฟ๐—ฒ๐—ป๐—ฒ๐˜€๐˜€ ๐—ฎ๐—ป๐—ฑ ๐——๐—ถ๐—ฎ๐—ด๐—ป๐—ผ๐˜€๐—ถ๐˜€

Increased awareness among clinicians and patients has led to higher diagnosis rates of TD, subsequently expanding the therapeutics market. Educational initiatives and campaigns are further aiding this trend.

๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฅ๐—ฒ๐˜€๐˜๐—ฟ๐—ฎ๐—ถ๐—ป๐˜๐˜€

๐—›๐—ถ๐—ด๐—ต ๐—–๐—ผ๐˜€๐˜ ๐—ผ๐—ณ ๐—ง๐—ต๐—ฒ๐—ฟ๐—ฎ๐—ฝ๐—ฒ๐˜‚๐˜๐—ถ๐—ฐ๐˜€

One of the major barriers to the widespread adoption of TD treatments is the high cost of advanced medications. Limited insurance coverage adds to the financial burden for patients.

๐—Ÿ๐—ถ๐—บ๐—ถ๐˜๐—ฒ๐—ฑ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฒ๐—ป๐—ฒ๐˜€๐˜€ ๐—ถ๐—ป ๐—–๐—ฒ๐—ฟ๐˜๐—ฎ๐—ถ๐—ป ๐—ฅ๐—ฒ๐—ด๐—ถ๐—ผ๐—ป๐˜€

Despite growing awareness, there are still gaps in diagnosing TD, particularly in rural or underserved areas, where access to specialized psychiatric care may be limited.

๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—–๐—ผ๐˜ƒ๐—ฒ๐—ฟ๐—ฎ๐—ด๐—ฒ

The comprehensive market report on the U.S. Tardive Dyskinesia Therapeutics Market delves into industry trends, key players, competitive landscape, and regional insights. It highlights drug performance, regulatory updates, and emerging growth opportunities.

๐—™๐—ผ๐—ฟ ๐—™๐˜‚๐—น๐—น ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—–๐—ผ๐˜ƒ๐—ฒ๐—ฟ๐—ฎ๐—ด๐—ฒ ๐—ฉ๐—ถ๐˜€๐—ถ๐˜: https://www.fortunebusinessinsights.com/u-s-tardive-dyskinesia-therapeutics-market-107826

๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—–๐—ผ๐—บ๐—ฝ๐—ฒ๐˜๐—ถ๐˜๐—ถ๐˜ƒ๐—ฒ ๐—Ÿ๐—ฎ๐—ป๐—ฑ๐˜€๐—ฐ๐—ฎ๐—ฝ๐—ฒ

Key market players like Neurocrine Biosciences and Teva Pharmaceutical Industries are investing heavily in research and development to introduce next-generation TD therapeutics. Strategic partnerships and clinical trials are shaping the competitive dynamics, enabling companies to strengthen their market presence.

๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฆ๐—ฒ๐—ด๐—บ๐—ฒ๐—ป๐˜๐˜€

๐—ฉ๐—ฎ๐—น๐—ฏ๐—ฒ๐—ป๐—ฎ๐˜‡๐—ถ๐—ป๐—ฒ ๐—ฆ๐—ฒ๐—ด๐—บ๐—ฒ๐—ป๐˜ ๐—Ÿ๐—ฒ๐—ฎ๐—ฑ๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฒ ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜

By drug, the valbenazine segment holds the largest share, attributed to its proven efficacy and minimal side effects. The drug's widespread acceptance among healthcare providers has further cemented its dominance in the market.

๐——๐—ฒ๐˜‚๐˜๐—ฒ๐˜๐—ฟ๐—ฎ๐—ฏ๐—ฒ๐—ป๐—ฎ๐˜‡๐—ถ๐—ป๐—ฒ ๐—ฆ๐—ฒ๐—ด๐—บ๐—ฒ๐—ป๐˜ ๐—˜๐—บ๐—ฒ๐—ฟ๐—ด๐—ถ๐—ป๐—ด ๐—ฎ๐˜€ ๐—ฎ ๐—–๐—ผ๐—บ๐—ฝ๐—ฒ๐˜๐—ถ๐˜๐—ผ๐—ฟ

Deutetrabenazine is also gaining traction due to its effectiveness in managing TD symptoms, making it a key player in the therapeutics landscape.

๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฅ๐—ฒ๐—ด๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—œ๐—ป๐˜€๐—ถ๐—ด๐—ต๐˜๐˜€

The U.S. leads the global TD therapeutics market, driven by a strong healthcare infrastructure, increased funding for psychiatric research, and high awareness levels. Regions such as California, New York, and Texas contribute significantly due to their dense population and advanced healthcare facilities.

๐—™๐˜‚๐˜๐˜‚๐—ฟ๐—ฒ ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฆ๐—ฐ๐—ผ๐—ฝ๐—ฒ

โ€ข Development of novel therapeutic mechanisms targeting TD-specific pathways.
โ€ข Increased focus on affordability through generic drug options and insurance reforms.
โ€ข Integration of AI and digital tools for early diagnosis and personalized treatment.
โ€ข Global expansion by key players into untapped markets to cater to unmet needs.

๐—–๐—ผ๐—ป๐—ฐ๐—น๐˜‚๐˜€๐—ถ๐—ผ๐—ป

The U.S. Tardive Dyskinesia Therapeutics Market continues to evolve with advancements in research, drug development, and patient care initiatives. Companies like Neurocrine Biosciences are leading the charge with innovative solutions that address the dual challenges of efficacy and psychiatric stability. With robust growth potential, the market is set to redefine care standards for patients with TD.

For more detailed insights, explore the U.S. Tardive Dyskinesia Therapeutics Market Report.

๐—–๐˜‚๐˜€๐˜๐—ผ๐—บ๐—ถ๐˜‡๐—ฒ ๐—ง๐—ต๐—ถ๐˜€ ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—”๐—ฐ๐—ฐ๐—ผ๐—ฟ๐—ฑ๐—ถ๐—ป๐—ด ๐—ง๐—ผ ๐—ฌ๐—ผ๐˜‚๐—ฟ ๐—–๐—ผ๐—ป๐˜ƒ๐—ฒ๐—ป๐—ถ๐—ฒ๐—ป๐—ฐ๐—ฒ: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/u-s-tardive-dyskinesia-therapeutics-market-107826

๐—–๐—ผ๐—ป๐˜๐—ฎ๐—ฐ๐˜ ๐—จ๐˜€:
Fortune Business Insightsโ„ข Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.:+1 833 909 2966 (Toll-Free)
U.K.: +44 808 502 0280 (Toll-Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

๐€๐›๐จ๐ฎ๐ญ ๐”๐ฌ:
Fortune Business Insightsโ„ข offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release U.S. Tardive Dyskinesia Therapeutics Market Size, Trends, Growth, Opportunities | Neurocrine Biosciences, Inc. and Teva Pharmaceutical Industries Ltd. here

News-ID: 3775165 • Views: โ€ฆ

More Releases from Fortune Business Insights

Used Cooking Oil Market Size, Share, Growth, Trends, 2032
Used Cooking Oil Market Size, Share, Growth, Trends, 2032
๐Œ๐š๐ซ๐ค๐ž๐ญ ๐Ž๐ฏ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ: The global used cooking oil market size was USD 7.09 billion in 2023 and is projected to grow from USD 7.54 billion in 2024 to USD 13.96 billion by 2032 at a CAGR of 8.00% during the forecast period (2024-2032). UCOs are fats and oils reused after processing for cooking or frying in food processing restaurants, industry, fast foods, and at the consumer level, in households. The impurity content, suchโ€ฆ
Doughnuts Market Size, Share, Growth, Trends, 2032
Doughnuts Market Size, Share, Growth, Trends, 2032
๐Œ๐š๐ซ๐ค๐ž๐ญ ๐Ž๐ฏ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ: The global doughnuts market size was USD 10.84 billion in 2023. The market is projected to expand from USD 11.22 billion in 2024 to USD 15.12 billion by 2032, exhibiting a CAGR of 3.79% during the forecast period. A doughnut, a small ring-shaped confection, is prepared by frying or baking leavened dough, offering a sweet indulgence. Increasing consumer demand for healthier options prompts brands to introduce innovative products, aligning withโ€ฆ
Honey Market Size, Share, Growth, Trends, 2032
Honey Market Size, Share, Growth, Trends, 2032
๐Œ๐š๐ซ๐ค๐ž๐ญ ๐Ž๐ฏ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ The global honey market size was valued at USD 8.94 billion in 2023 and is projected to grow from USD 9.40 billion in 2024 to USD 15.59 billion by 2032, exhibiting a CAGR of 6.52% during the forecast period 2024-2032. Rising demand for organic and healthy alternatives to sugar to propel market growth. Fortune Business Insightsโ„ข provides this information in its report titled "Honey Market, 2024-2032." ๐†๐ž๐ญ ๐€ ๐…๐ซ๐ž๐ž ๐’๐š๐ฆ๐ฉ๐ฅ๐žโ€ฆ
Pasta Market Size, Share, Growth, 2032
Pasta Market Size, Share, Growth, 2032
๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐Ž๐ฏ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ: The global pasta market size was valued at USD 68.35 billion in 2023 and is projected to grow from USD 71.42 billion in 2024 to USD 100.24 billion by 2032, exhibiting a CAGR of 5.47% during the forecast period of 2024-2032. Pasta is a largely consumed, easy-to-make, and an affordable food product. The increasing and regular evolution of pasta propels the pasta market growth during the forecast period. The risingโ€ฆ

All 5 Releases


More Releases for Tardive

Tardive Dyskinesia Drugs Market Research Analysis, Applications, Demands and Gro โ€ฆ
Global Tardive Dyskinesia Drugs Market: The report provides a valuable source of insightful data for business strategists and competitive analysis of Tardive Dyskinesia Drugs Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges. It alsoโ€ฆ
Tardive Dyskinesia Drugs Market Competitor Landscape, Opportunity Analysis, Grow โ€ฆ
Tardive neurological disorder (TD) may be a kind of dyskinesia that's tough to treat. it's a nerve disorder characterised by involuntary movements like jaw, lips, and tongue, thought-about as grimacing, protrusive the tongue out, and lip smack. another symptoms square measure a private experiencing involuntary movement of the lower and higher extremities and additionally respiratory choking. Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/218 consistent with Center for Drug analysis and analysis, dyskinesia willโ€ฆ
Antioxidants May Aid in the Treatment of Tardive Dyskinesia
Memphis, TN (May 9, 2019) โ€“ Today, The Primary Care Companion for CNS Disorders published a case report on the use of antioxidants in the treatment of tardive dyskinesia. While new pharmacologic discoveries have occurred in the area of movement disorders, their use comes with a large price tag. Thus, for mild cases, clinicians may want to seek out more cost-effective options. Antioxidants may serve a role in the preventionโ€ฆ
Tardive Dyskinesia Market (TD) Developing CAGR During the Forecast 2018-2025
Global Tardive Dyskinesia Market Size, Status and Forecast 2018-2025 market research report, has been prepared based on a deep market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this Global market. Download PDF Brochure of Tardive Dyskinesia Market spread across 97 Pages, Profiling Companies and Supported withโ€ฆ
Tardive Dyskinesia (TD) Treatment Market Industry Analysis, Trend and Growth, 20 โ€ฆ
Tardive dyskinesia (TD) is a disorder caused by a prolonged use of antipsychotic drugs by patients suffering from schizophrenia and other neuroleptic disorders. It is characterized by involuntary and uncontrolled movements of body parts such as eyeballs, lips, and tongue. Although tardive dyskinesia commonly occurs in patients who have been treated with antipsychotic medication for long periods, it also occurs occasionally in other conditions such as fetal alcohol syndrome, developmentalโ€ฆ
Tardive Dyskinesia (TD) Treatment Market Forcasted for Accelerated Growth by 202 โ€ฆ
Global Tardive Dyskinesia (TD) Treatment Market: Overview Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. The side effect of the neuroleptics medicines is tardive dyskinesia.โ€ฆ